Summary
Genetic breakthroughs have implications for both Parkinson disease and epilepsy. Evidence suggests that the monoclonal antibody Syn303 may represent a therapeutic advance in treating Parkinson disease. The discovery of genetic mutations and variants in families and others with epilepsy is providing groundbreaking insights regarding potential treatment options and surgical considerations.
- Parkinson disease
- epilepsy
- genetics
- monoclonal antibodies
- Syn303
- α-synuclein
- FFEVF
- DEPDC5
- mTOR
- neurology clinical trials
- extrapyramidal & movement disorders
- neurology genomics
- © 2015 SAGE Publications